Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

RG6076 (CD19-4-1BBL): CD19-Targeted 4-1BB Ligand Combination with Glofitamab As an Off-the-Shelf, Enhanced T-Cell Redirection Therapy for B-Cell Malignancies

Sylvia Herter, PhD, Johannes Sam, PhD, Claudia Ferrara Koller, PhD, Sarah Diggelmann, Esther Bommer, Anne Schönle, Christina Claus, PhD, Marina Bacac, PhD, Christian Klein, PhD, Pablo Umana, PhD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-134782

Published: 2020

Journal Articles

Targeting Intracellular WT1 in AML Utilizing a T Cell Bispecific Antibody Construct: Augmenting Efficacy through Combination with Lenalidomide

Blood (2019) 134 (Supplement_1): 4450.

https://doi.org/10.1182/blood-2019-130121

Published: 2019

Journal Articles

The Triple Combination of the CD20 Antibody Obinutuzumab with the Bcl-2 Inhibitor Venetoclax (GDC-199) and the MDM2 Inhibitor Idasanutlin Results in Superior Efficacy and Long Term Response in Wildtype p53 NHL Tumor Models

Frank Herting, PhD, Thomas Friess, PhD, Pablo Umaña, PhD, Middleton Steven, PhD, Christian Klein, PhD

Blood (2016) 128 (22): 4178.

https://doi.org/10.1182/blood.V128.22.4178.4178

Published: 2016

Journal Articles

CD20 Tcb (RG6026), a Novel "2:1" T Cell Bispecific Antibody for the Treatment of B Cell Malignancies

Marina Bacac, PhD, Pablo Umaña, PhD, Sylvia Herter, PhD, Sara Colombetti, PhD, Johannes Sam, PhD, Marine Le Clech, Anne Freimoser-Grundschober, PhD, Marine Richard, Valeria Nicolini, PhD, Christian Gerdes, PhD, Laurent Lariviere, PhD, Christiane Neumann, PhD, Christian Klein, PhD

Blood (2016) 128 (22): 1836.

https://doi.org/10.1182/blood.V128.22.1836.1836

Published: 2016

Journal Articles

A New Class of T-Cell Bispecific Antibodies for the Treatment of Multiple Myeloma, Binding to B Cell Maturation Antigen and CD3 and Showing Potent, Specific Antitumor Activity in Myeloma Cells and Long Duration of Action in Cynomolgus Monkeys

Blood (2015) 126 (23): 2998.

https://doi.org/10.1182/blood.V126.23.2998.2998

Published: 2015

Journal Articles

The PI3K Delta Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function and B Cell Depletion Mediated By Obinutuzumab (GA101) and Rituximab

Sylvia Herter, PhD, Adam Palazzo, Marina Bacac, PhD, Laura Grosmaire, MS, Christian Frey, PhD, Stefan Pflanz, PhD, Jia Liu, PhD, Stacey Tannheimer, PhD, Pablo Umana, PhD, Christian Klein, PhD, Christophe Queva, PhD

Blood (2014) 124 (21): 3342.

https://doi.org/10.1182/blood.V124.21.3342.3342

Published: 2014

Journal Articles

Obinutuzumab (GA101) Is Less Prone to Antagonism of Immune Effector Function By Ibrutinib Than Rituximab in Vitro and in Vivo

Sylvia Herter, PhD, Idit Sagiv-Barfi, PhD, Cariad Chester, Mohith Sadaram, BS, Jonathan Hebb, MD, Debra K Czerwinski, Narendiran Rajasekaran, PhDMSc, Marina Bacac, PhD, Pablo Umana, PhD, Ron Levy, MD, Christian Klein, PhD, Holbrook E Kohrt, MD PhD

Blood (2014) 124 (21): 1765.

https://doi.org/10.1182/blood.V124.21.1765.1765

Published: 2014

Journal Articles

Obinutuzumab (GA101) More Potently Engages Phagocytic-Lineage Cells Resulting In Enhanced Monocyte and Macrophage Activity When Compared To Rituximab and Ofatumumab

Sylvia Herter, PhD, Christian Klein, PhD, Pablo Umana, PhD, Marina Bacac

Blood (2013) 122 (21): 5136.

https://doi.org/10.1182/blood.V122.21.5136.5136

Published: 2013

Journal Articles

Novel Tumor-Targeted, Engineered IL-2 Variant (IL2v)-Based Immunocytokines For Immunotherapy Of Cancer

Blood (2013) 122 (21): 2278.

https://doi.org/10.1182/blood.V122.21.2278.2278

Published: 2013

Journal Articles

Differential Patterns of Gene Expression and CD20 Localisation by the Type II Anti-CD20 Antibody Obinutuzumab (GA101) Compared with the Type I Antibody Rituximab Suggests Binding to Functionally Distinct CD20 Subpopulations on B-Cell Lymphoma Cell Lines,

Gerhard Niederfellner, Olaf Mundigl, Alexander Lifke, Andreas Franke, Ute Baer, Helmut Burtscher, Daniela Maisel, Anton Belousov, K. Michael Weidner, PhD, Pablo Umana, PhD, Christian Klein, PhD

Blood (2011) 118 (21): 3721.

https://doi.org/10.1182/blood.V118.21.3721.3721

Published: 2011

Journal Articles

Enhanced Activity of GA101, a Novel Type II, Glycoengineered CD20 Antibody, In Combination with Bendamustine or Fludarabine, and with the Bcl-2 Family Inhibitors ABT-737 or ABT-263

Frank Herting, MD, Sabine Bader, Pablo Umana, PhD, Christian Klein, PhD

Blood (2010) 116 (21): 3915.

https://doi.org/10.1182/blood.V116.21.3915.3915

Published: 2010

Journal Articles

Superior Efficacy of the Novel Type II, Glycoengineered CD20 Antibody GA101 vs . the Type I CD20 Antibodies Rituximab and Ofatumumab

Sylvia Herter, Inja Waldhauer, Tina Otz, Frank Herting, Sabine Lang, Valeria Nicolini, Michaela Römmele, Thomas Friess, Erwin Van Puijenbroek, Marina Bacac, K. Michael Weidner, PhD, Christian Gerdes, Pablo Umana, PhD, Christian Klein, PhD

Blood (2010) 116 (21): 3925.

https://doi.org/10.1182/blood.V116.21.3925.3925

Published: 2010

Journal Articles

CD40 Stimulation Sensitizes CLL Cells to CD20-Triggered Cell Death by Rituximab and GA101 Via a Different Mechanism

Margot Jak, Gregor van Bochove, Christian Klein, PhD, Pablo Umana, PhD, Eric Eldering, PhD, Marinus H.J. Van Oers, MD, PhD

Blood (2010) 116 (21): 3979.

https://doi.org/10.1182/blood.V116.21.3979.3979

Published: 2010

Journal Articles

GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Mediates Superior Efficacy in a Variety of NHL Xenograft Models in Comparison to Rituximab.

Thomas Friess, PhD, Christian Gerdes, PhD, Adam Nopora, PhD, Monika Patre, PhD, Susanne Preiss, PhD, Erwin van Puijenbroek, Christine Schuell, PhD, Sabine Bauer, PhD, Pablo Umana, PhD, Christian Klein, PhD

Blood (2007) 110 (11): 2338.

https://doi.org/10.1182/blood.V110.11.2338.2338

Published: 2007

Journal Articles

GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Exhibits Superior Anti-Tumor Efficacy and Superior Tissue B Cell Depletion In Vivo.

Blood (2007) 110 (11): 2348.

https://doi.org/10.1182/blood.V110.11.2348.2348

Published: 2007

Journal Articles

Novel 3 rd Generation Humanized Type II CD20 Antibody with Glycoengineered Fc and Modified Elbow Hinge for Enhanced ADCC and Superior Apoptosis Induction.

Blood (2006) 108 (11): 229.

https://doi.org/10.1182/blood.V108.11.229.229

Published: 2006

Journal Articles

Enhanced Potency of Glycoengineered Anti-CD52 Monoclonal Antibodies (MAbs).

Martin J.S. Dyer, MD, PhD, Samuel Moser, PhD, Peter Brünker, PhD, Pru Bird, PhD, Neil Almond, PhD, Ursula Püentener, PhD, Luise M.W. Wheat, PhD, Emma Bolam, Eleanor Berrie, PhD, Roger Grau, PhD, Emma Buckby, Ben Kennedy, MD, Richard Stebbings, PhD, Geoff Hale, PhD, Pablo Umana, PhD

Blood (2005) 106 (11): 2958.

https://doi.org/10.1182/blood.V106.11.2958.2958

Published: 2005

NARROW

RG6076 (CD19-4-1BBL): CD19-Targeted 4-1BB Ligand Combination with Glofitamab As an Off-the-Shelf, Enhanced T-Cell Redirection Therapy for B-Cell Malignancies

Targeting Intracellular WT1 in AML Utilizing a T Cell Bispecific Antibody Construct: Augmenting Efficacy through Combination with Lenalidomide

The Triple Combination of the CD20 Antibody Obinutuzumab with the Bcl-2 Inhibitor Venetoclax (GDC-199) and the MDM2 Inhibitor Idasanutlin Results in Superior Efficacy and Long Term Response in Wildtype p53 NHL Tumor Models

CD20 Tcb (RG6026), a Novel "2:1" T Cell Bispecific Antibody for the Treatment of B Cell Malignancies

A New Class of T-Cell Bispecific Antibodies for the Treatment of Multiple Myeloma, Binding to B Cell Maturation Antigen and CD3 and Showing Potent, Specific Antitumor Activity in Myeloma Cells and Long Duration of Action in Cynomolgus Monkeys

The PI3K Delta Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function and B Cell Depletion Mediated By Obinutuzumab (GA101) and Rituximab

Obinutuzumab (GA101) Is Less Prone to Antagonism of Immune Effector Function By Ibrutinib Than Rituximab in Vitro and in Vivo

Obinutuzumab (GA101) More Potently Engages Phagocytic-Lineage Cells Resulting In Enhanced Monocyte and Macrophage Activity When Compared To Rituximab and Ofatumumab

Novel Tumor-Targeted, Engineered IL-2 Variant (IL2v)-Based Immunocytokines For Immunotherapy Of Cancer

Differential Patterns of Gene Expression and CD20 Localisation by the Type II Anti-CD20 Antibody Obinutuzumab (GA101) Compared with the Type I Antibody Rituximab Suggests Binding to Functionally Distinct CD20 Subpopulations on B-Cell Lymphoma Cell Lines,

Enhanced Activity of GA101, a Novel Type II, Glycoengineered CD20 Antibody, In Combination with Bendamustine or Fludarabine, and with the Bcl-2 Family Inhibitors ABT-737 or ABT-263

Superior Efficacy of the Novel Type II, Glycoengineered CD20 Antibody GA101 vs . the Type I CD20 Antibodies Rituximab and Ofatumumab

CD40 Stimulation Sensitizes CLL Cells to CD20-Triggered Cell Death by Rituximab and GA101 Via a Different Mechanism

GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Mediates Superior Efficacy in a Variety of NHL Xenograft Models in Comparison to Rituximab.

GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Exhibits Superior Anti-Tumor Efficacy and Superior Tissue B Cell Depletion In Vivo.

Novel 3 rd Generation Humanized Type II CD20 Antibody with Glycoengineered Fc and Modified Elbow Hinge for Enhanced ADCC and Superior Apoptosis Induction.

Enhanced Potency of Glycoengineered Anti-CD52 Monoclonal Antibodies (MAbs).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only